Van Andel Research Institute

Van Andel Research Institute

333 Bostwick Ave

Grand Rapids, MI 49503

United States

Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma

We are working to develop new approaches to target the gene that causes Ewing sarcoma tumors to grow and spread throughout the body, a gene called EWS-FLI1. As we move these therapies in the clinic, there needs to be a way to determine if our new therapies are blocking the EWS-FLI1 drug target.

Development of Mithramycin Analogs for Ewing sarcoma

Ewing Sarcoma

Background

A promising drug target for Ewing’s sarcoma is a protein called EWS-FLI1. This is a type of protein called a transcription factor which is thought by many to be an “undruggable target.”

Optimizing the Trabectedin Induced Differentiation of Ewing sarcoma Cells into Adipocytes

Ewing Sarcoma

Alex's Lemonade Stand Foundation for Childhood Cancer